Biotech Roundup: ASCO, BIO, Drug Setbacks, Incubators & More
Xconomy
JUNE 10, 2016
The results give the company confidence it can expand its tests to screen for early cancer in high-risk people who are otherwise healthy. As the conference wrapped up, a Morgan Stanley analyst noted that Pfizer the previous week had raised its drug prices nine percent, continuing a regular pattern of price increases.
67 
Let's personalize your content